Literature DB >> 26892759

Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.

Chao Dong1, Ji-chun Zhang1, Wei Yao1, Qian Ren1, Chun Yang1, Min Ma1, Mei Han1, Ryo Saito2, Kenji Hashimoto3.   

Abstract

Inflammation plays a role in the pathophysiology of depression. The purpose of this study is to examine whether the selective serotonin reuptake inhibitor (SSRI) escitalopram, its inactive enantiomer R-citalopram, and selective noradrenaline reuptake inhibitor (NRI) reboxetine, show anti-inflammatory and antidepressant effects in an inflammation-induced model of depression. Pretreatment with escitalopram (1, 3, or 10mg/kg, i.p.) markedly blocked an increase in the serum levels of pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α), after a single administration of lipopolysaccharide (LPS; 0.5mg/kg). Furthermore, escitalopram (3 or 10mg/kg) significantly increased the serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) by a single administration of LPS. In contrast, pretreatment with R-citalopram (10mg/kg, i.p.) or reboxetine (10mg/kg, i.p.) did not affect the alterations in serum levels of TNF-α and IL-10 after LPS administration. Co-administration of reboxetine with escitalopram did not show anti-inflammatory effects. Pretreatment with escitalopram (10mg/kg) significantly attenuated LPS-induced increase of the immobility time in the tail-suspension test (TST) and forced swimming test (FST). In contrast, pretreatment with R-citalopram (10mg/kg), or reboxetine (10mg/kg) did not alter LPS-induced increase of immobility time of TST and FST. Interestingly, co-administration of reboxetine with escitalopram did not show antidepressant effect in this model. These findings suggest that escitalopram, but not R-citalopram and reboxetine, has anti-inflammatory and antidepressant effects in LPS-treated model of depression, and that reboxetine can antagonize the effects of escitalopram in the inflammation model. Therefore, it is likely that serotonergic system plays a key role in the pathophysiology of inflammation-induced depression.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant; Depression; Inflammation; Noradrenaline; Serotonin

Mesh:

Substances:

Year:  2016        PMID: 26892759     DOI: 10.1016/j.pbb.2016.02.005

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  15 in total

Review 1.  The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies.

Authors:  Vlad Dionisie; Gabriela Adriana Filip; Mihnea Costin Manea; Mirela Manea; Sorin Riga
Journal:  Inflammopharmacology       Date:  2020-11-08       Impact factor: 4.473

2.  Effect of lipopolysaccharide on circadian clock genes Per2 and Bmal1 in mouse ovary.

Authors:  Takashi Shimizu; Kaya Watanabe; Nozomi Anayama; Koyomi Miyazaki
Journal:  J Physiol Sci       Date:  2017-02-17       Impact factor: 2.781

Review 3.  Inflammation and the Silent Sequelae of Stroke.

Authors:  Kyra J Becker
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

4.  Combination of electroconvulsive stimulation with ketamine or escitalopram protects the brain against inflammation and oxidative stress induced by maternal deprivation and is critical for associated behaviors in male and female rats.

Authors:  Helena M Abelaira; Thayse Rosa; Airam B de Moura; Natalia M Andrade; Nicoly S Martinello; Larissa R Maciel; Maria Eduarda M Botelho; Laura A Borba; Beatriz C Chede; Camila O Arent; Larissa Joaquim; Sandra Bonfante; Lucinéia G Danielski; Talita Tuon; Fabricia Petronilho; João Quevedo; Gislaine Z Réus
Journal:  Mol Neurobiol       Date:  2022-01-07       Impact factor: 5.590

5.  What Animal Models Can Tell Us About Long-Term Psychiatric Symptoms in Sepsis Survivors: a Systematic Review.

Authors:  Felipe Dal-Pizzol; Gabriela Ferreira de Medeiros; Monique Michels; Aurélien Mazeraud; Fernando Augusto Bozza; Cristiane Ritter; Tarek Sharshar
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

6.  Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation.

Authors:  Min Ma; Qian Ren; Chun Yang; Ji-Chun Zhang; Wei Yao; Chao Dong; Yuta Ohgi; Takashi Futamura; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2016-11-15       Impact factor: 4.530

7.  Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.

Authors:  Chao Dong; Ji-Chun Zhang; Wei Yao; Qian Ren; Min Ma; Chun Yang; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Int J Neuropsychopharmacol       Date:  2017-03-01       Impact factor: 5.176

Review 8.  Gene-disease association study of tumor necrosis factor-α G-308A gene polymorphism with risk of major depressive disorder: A systematic review and meta-analysis.

Authors:  Xin Wang; Hongxiu Zhang; Xianling Cao; Wei Shi; Xiaoyu Zhou; Qian Chen; Ke Ma
Journal:  Brain Behav       Date:  2020-04-19       Impact factor: 2.708

Review 9.  Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective.

Authors:  Kenji Hashimoto
Journal:  Front Pharmacol       Date:  2018-10-16       Impact factor: 5.810

10.  Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.

Authors:  Justin Fortune Creeden; Ali Sajid Imami; Hunter M Eby; Cassidy Gillman; Kathryn N Becker; Jim Reigle; Elissar Andari; Zhixing K Pan; Sinead M O'Donovan; Robert E McCullumsmith; Cheryl B McCullumsmith
Journal:  Biomed Pharmacother       Date:  2021-02-25       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.